In addition, lifetime genetic lowering of ANGPTL4 was observed to reduce the risk of T2D, indicating that ANGPTL4 inhibition might provide additional benefits to patients with T2D. This evidence concerns the gene ANGPTL4 and type 2 diabetes mellitus.